^
    10d
    BGB-11417-203: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia (clinicaltrials.gov)
    P2, N=114, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    17d
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    22d
    CELESTIAL-TNCLL: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P3, N=652, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    29d
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeiGene | Trial completion date: Dec 2032 --> Dec 2031
    Trial completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    1m
    BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Christine Ryan | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • Brukinsa (zanubrutinib) • bendamustine • Truxima (rituximab-abbs) • sonrotoclax (BGB-11417)
    1m
    A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    2ms
    BOSon: Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    3ms
    Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=125, Active, not recruiting, BeiGene | Trial completion date: Aug 2027 --> Jan 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    sonrotoclax (BGB-11417)
    3ms
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, BeiGene
    New P1 trial
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    3ms
    Risk-stratified treatment of sonrotoclax combined with chemotherapy in patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II stud (ChiCTR2400090001)
    P2, N=47, Recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2
    Enrollment open • Phase classification
    |
    sonrotoclax (BGB-11417)
    4ms
    A phase II clinical study exploring the treatment of relapsed/refractory acute myeloid leukemia (AML) patients with sonrotoclax combined with azacitidine and HAG pre stimulation regimen (ChiCTR2500105133)
    P2, N=27, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P2 trial
    |
    cytarabine • azacitidine • Synribo (omacetaxine mepesuccinate) • sonrotoclax (BGB-11417)
    4ms
    Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=37, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2028 --> Jan 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)